Queen's University Belfast

Executives from eBay and Golden State Foods Join GS1 US Board of Governors

Retrieved on: 
Monday, December 5, 2022
School, United Nations, Sysco, Electronics, Vertical service code, Golden State Foods, Surgeon, Carnegie Mellon School of Computer Science, Computer science, The J.M. Smucker Company, Gaffney, GS1, RFID, Yahoo!, UNSPSC, Topco, EPC, SEO, Labs, Research, Royal College of Physicians and Surgeons of Canada, Intelligence, Economics, Dot Foods, Procter & Gamble, University of California, Santa Cruz Silicon Valley Initiatives, Queen's University Belfast, Restaurant, Multimedia, GS1 US, University, Safety, Digital transformation, Engineering, Physician, Organization, PepsiCo, Golden, Doctor of Philosophy, The Coca-Cola Company, Massachusetts Institute of Technology, Wegmans, EBay, Management, Online shopping

EWING, N.J. , Dec. 5, 2022 /PRNewswire/ -- GS1 US® has elected the following executives to the GS1 US Board of Governors: Scott Gaffney, vice president, product and engineering for search, browse, search engine optimization (SEO) and search monetization, eBay; and Brian Dick, executive vice president and chief operating officer, Golden State Foods.

Key Points: 
  • Prior to eBay, Gaffney was the vice president of engineering and research at Yahoo!
  • At Golden State Foods, Dick oversees all global food manufacturing and logistics operations for the $6 billion supplier to the foodservice and retail industries.
  • The GS1 US Board of Governors comprisesexecutives from leading organizations including:Amazon;The Coca-Cola Company; Dot Foods, Inc.;eBay, Inc.;Golden State Foods; Google; The J.M.
  • GS1 US also manages the United Nations Standard Products and Services Code (UNSPSC).

PharmaTher Announces Positive Results from Study For Ketamine Microneedle Patch

Retrieved on: 
Wednesday, June 29, 2022
FDA, OTCQB, Patient, Ketamine, Chronic pain, Needle, Trial of the century, Betaine, GLOBE, Substance abuse, Company, Queen's University Belfast, MAP, GMP, Suicidal ideation, CSE, Post-traumatic stress disorder, Plasma, LTS, Lists of diseases, Depression, Pain, Compliance, Inhalation, Holding, GLP, Laboratory rat, Microneedle, Skin, Mental health, Pain disorder, Pharmaceutical industry, Vaccine

TORONTO, June 29, 2022 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a leader in specialty ketamine pharmaceuticals, is pleased to announce that it has successfully completed its research study evaluating the Company’s patented hydrogel-forming microneedle patch, PHARMAPATCH™, to deliver ketamine and KETABET™ (ketamine and betaine anhydrous), which aims to prevent the potential side effects of repeated ketamine treatment for depression and other indications, including suicidal ideation, substance abuse, post-traumatic stress disorder, neurological disorders, and chronic pain.

Key Points: 
  • Research results were published in a paper titled Hydrogel-forming microneedle arrays as a therapeutic option for transdermal esketamine delivery1.
  • At regular time intervals during the 48-hour rat study, blood sample results demonstrated that PHARMAPATCH was able to deliver plasma levels of ketamine (between 70-200 ng/mL) in a controlled manner throughout the study.
  • The Company is preparing for a planned Phase 2 clinical study to allow for ketamine and KETABET microneedle patch evaluation in treatment-resistant depression and chronic pain under the FDA 505(b)(2) regulatory pathway.
  • The Companys patented hydrogel-forming microneedle (MN) patch aims to deliver ketamine for intradermal administration to treat various mental health, neurological and pain disorders.

IVBH's Strategic Partnership with Sonrai Analytics to Advance Novel Early Detection Precision Diagnostics

Retrieved on: 
Tuesday, June 28, 2022
Efficiency, Diagnosis, Queen's University Belfast, IRELAND, Paradigm, Patient, Breast cancer, Degenerative disease, Love, Engineering, NAFLD, Intelligence, National Health Service, Biomarker, R, Cancer, Company, Disease, Scale, Lung cancer, CRO, United Kingdom, Differential diagnoses of depression, Partnership, Lists of diseases, Technology, RNA, Health, Machine learning, AI, Non-alcoholic fatty liver disease, Time, DRS, PCR, Eye, Data science, IV, Multimedia, CSV, Medical device, Medical imaging, Gigapixel image, Songhai

NEWPORT BEACH, Calif. and BELFAST, NORTHERN IRELAND, June 28, 2022 /PRNewswire/ -- IV BioHoldings (IVBH) – a clinical-stage bio-platform company that conceives, creates and scales first-generation precision health solutions that improve the detection, diagnosis and treatment of disease – has partnered with Sonrai Analytics. Sonrai's customized, advanced AI applications will bolster IVBH's analytic capabilities, allowing for improvements on clinical insights for the company's pipeline of noninvasive diagnostics for lung cancer, non-alcoholic fatty liver disease and breast cancer.

Key Points: 
  • "The IVBH-Sonrai partnership is the ultimate expression of abundance, leveraging AI to democratize healthcare R&D and accelerating massive value creation for all stakeholders through our novel and highly efficient decentralized partnership model."
  • Sonrai Analytics based in Belfast, Northern Ireland adopts artificial intelligence approaches to help biotech, CRO and pharma companies efficiently utilize their data.
  • IVBH is a bio platform company that conceives, creates, and scales first-generation precision health solutions that radically improve the detection, diagnosis, and treatment of disease.
  • Darragh McArt and Deva Senevirathne as a technology start-up within healthcare and precision medicine domains, spun-out of Queen's University Belfast.

Oxford Science Enterprises Strengthens Investment Teams with Two New Appointments

Retrieved on: 
Thursday, March 31, 2022
Master, Principal, Accenture, Partner, Strategic management, Merck Group, University, Investment, Johnson Health Tech, Queen's University Belfast, Survival, Research, Doctor of Philosophy, Food technology, Tate, Associate, University of Oxford, OXFORD, University of York, Technology, UnitedHealth Group, Department of Computer Science, University of Oxford, List of life sciences, Food, Merck, Bachelor of Science, Management, Financial services, Optum, Genetics

OXFORD, England, March 31, 2022 /PRNewswire/ -- Oxford Science Enterprises, the Science Business Builder and preferred investment partner of the University of Oxford, today announces further strengthening of its investment teams with the appointments of Heather Roxborough PhD as Partner, Health Tech and Wallace Wallace MPhil as Associate, Life Sciences.

Key Points: 
  • - Heather Roxborough PhD, former Partner at Optum Ventures, joins as Partner, Health Tech
    OXFORD, England, March 31, 2022 /PRNewswire/ --Oxford Science Enterprises, the Science Business Builder and preferred investment partner of the University of Oxford, today announces further strengthening of its investment teams with the appointments of Heather Roxborough PhD as Partner, Health Tech and Wallace Wallace MPhil as Associate, Life Sciences.
  • Alexis Dormandy, CEO Oxford Science Enterprises, said:"I am thrilled to welcome Heather and Wallace.
  • Wallace joins Oxford Science Enterprises from M-Ventures, the corporate venture capital arm of Merck KGaA, where she supported the life sciences investment team across scientific due diligence and portfolio management.
  • We are Oxford Science Enterprises, the Science Business Builder.

Oxford Science Enterprises Strengthens Investment Teams with Two New Appointments

Retrieved on: 
Thursday, March 31, 2022
Master, Principal, Accenture, Partner, Strategic management, Merck Group, University, Investment, Johnson Health Tech, Queen's University Belfast, Survival, Research, Doctor of Philosophy, Food technology, Tate, Associate, University of Oxford, OXFORD, University of York, Technology, UnitedHealth Group, Department of Computer Science, University of Oxford, List of life sciences, Food, Merck, Bachelor of Science, Management, Financial services, Optum, Genetics

OXFORD, England, March 31, 2022 /PRNewswire/ -- Oxford Science Enterprises, the Science Business Builder and preferred investment partner of the University of Oxford, today announces further strengthening of its investment teams with the appointments of Heather Roxborough PhD as Partner, Health Tech and Wallace Wallace MPhil as Associate, Life Sciences.

Key Points: 
  • - Heather Roxborough PhD, former Partner at Optum Ventures, joins as Partner, Health Tech
    OXFORD, England, March 31, 2022 /PRNewswire/ --Oxford Science Enterprises, the Science Business Builder and preferred investment partner of the University of Oxford, today announces further strengthening of its investment teams with the appointments of Heather Roxborough PhD as Partner, Health Tech and Wallace Wallace MPhil as Associate, Life Sciences.
  • Alexis Dormandy, CEO Oxford Science Enterprises, said:"I am thrilled to welcome Heather and Wallace.
  • Wallace joins Oxford Science Enterprises from M-Ventures, the corporate venture capital arm of Merck KGaA, where she supported the life sciences investment team across scientific due diligence and portfolio management.
  • We are Oxford Science Enterprises, the Science Business Builder.

PharmaTher Provides Business Highlights and Releases Annual Financials for Fiscal Year Ended May 31, 2021

Retrieved on: 
Tuesday, September 7, 2021

TORONTO, Sept. 07, 2021 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the Company or PharmaTher) (OTCQB: PHRRF) (CSE: PHRM), a clinical-stage psychedelics biotech company, today released business highlights and financial results for its fiscal year ended May 31, 2021.

Key Points: 
  • TORONTO, Sept. 07, 2021 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the Company or PharmaTher) (OTCQB: PHRRF) (CSE: PHRM), a clinical-stage psychedelics biotech company, today released business highlights and financial results for its fiscal year ended May 31, 2021.
  • PharmaTher is now focused on completing its drug delivery research programs and clinical studies for the use of ketamine in Parkinsons disease, depression, and ALS.
  • Cash and cash equivalents ($2,778,081) and Investment ($3,100,000) for a total of $5,878,081 as of May 31, 2021.
  • Net loss was $2,664,196 for the financial year ended May 31, 2021.

New Research By Orbis International, Queen's University Belfast and Wenzhou Medical University Suggests Glaucoma Screening Could Save Three Million Years Of Blindness In China

Retrieved on: 
Thursday, May 23, 2019
RTT, Health, Blindness, Ophthalmology, Glaucoma, Orbis International, Vision, Visual impairment, Orbis, Wenzhou Medical University, Wenzhou, Queen's University Belfast

NEW YORK, May 23, 2019 /PRNewswire/ -- New research by Orbis International, Queen's University Belfast and Wenzhou Medical University has found that offering glaucoma screening in China could be highly cost-effective while reducing blindness among the population.

Key Points: 
  • NEW YORK, May 23, 2019 /PRNewswire/ -- New research by Orbis International, Queen's University Belfast and Wenzhou Medical University has found that offering glaucoma screening in China could be highly cost-effective while reducing blindness among the population.
  • Glaucoma is the leading cause of irreversible blindness globally, affecting 64.3 million people worldwide.
  • Highly effective treatments, including eye drops, laser and incisional surgery are proven to greatly reduce the risk of blindness.
  • The research was a collaboration between Queen's University Belfast, Wenzhou Medical University, Renmin University of China and Orbis International.